Kornimate/medical-research-clean huggingface dataset:
a scaleable video coaching intervention for opioid-using mothers

Conditions: Child Behavior; Parent-Child Relations; Substance Use; Substance Abuse

Summary: this study will adapt and evaluate a novel, innovative, and highly scalable parenting intervention that employs video coaching to target responsive parenting, filming interactions to nurture development (find), among women who have been referred to or are in treatment for opioid misuse/addiction.

the overall objective of this study is to conduct a randomized trial with a sample of opioid-using women who are in or have been referred for treatment through outpatient and inpatient services and have a child aged 0-36 months. we will use a longitudinal design with an active control condition to test the central hypothesis that associations between (a) increases in responsive caregiving and (b) subsequent caregiver opioid addiction recovery, psychological well-being, and child developmental and biobehavioral outcomes (secondary targets), will be partially mediated through (c) changes in caregiver executive functioning, reward responsiveness, and parent self-concept. the rationale for this work is that it simultaneously addresses the unmet needs of a large, significantly underserved population and allows for a rigorous test of our conceptual model, which specifies hypothesized underlying mechanisms and differential impact.

Eligibility criteria:
inclusion criteria: * must be an adult (18-50 years of age) * must be the biological parent of a child between the ages of 0-48 months of age * must have received, or be currently receiving, treatment for a substance use disorder for any dsm-5 class of substance use disorder except caffeine or tobacco. this includes alcohol, cannabis, hallucinogens, inhalants, opioids, sedatives, hypnotics/anxiolytics, and stimulants. * must have their child at least two days each week at study entry exclusion criteria: * metal implants, metal fragments, pacemakers, or other electronic medical implants * claustrophobic * weigh \> 550 lbs * women who are or think they may be pregnant * history of neurological disorders * left-handed

Keywords: parent training early adversity early intervention manualized intervention high-risk children parenting fmri
a study to compare the safety and efficacy of romosozumab (amg 785) versus placebo in men with osteoporosis

Conditions: Osteoporosis in Men

Summary: the study is designed to evaluate if treatment with romosozumab once a month for 12 months compared with placebo is effective in increasing bone mineral density (bmd) at the lumbar spine. additionally, the study will assess the effect of treatment with romosozumab for 12 months compared with placebo on bmd at the femoral neck and total hip.


Eligibility criteria:
inclusion criteria: * must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age * must have a bmd t score ≤ -2.50 at the spine or hip, or bmd t score ≤ -1.50 at the spine or hip and a history of fragility nonvertebral fracture or vertebral fracture. exclusion criteria: * a bmd t score ≤ -3.50 at the hip, * history of hip fracture * severe metabolic bone diseases * significant laboratory abnormalities * recent treatment with agents affecting bone metabolism

Keywords: osteoporosis in men
evaluation of safety and efficacy of 17-beta estradiol in treatment of atrophic vaginitis: an extension trial

Conditions: Menopause; Postmenopausal Vaginal Atrophy

Summary: this trial was conducted in the united states of america (usa). this trial aimed to evaluate safety and efficacy of 17-beta estradiol in the treatment of atrophic vaginitis.


Eligibility criteria:
inclusion criteria: * generally healthy * postmenopausal * hysterectomized or non-hysterectomized * moderate or severe vaginal dryness and soreness * successful completion of the study vag/pd/009/usa exclusion criteria: * known, suspected, or past history of breast cancer * known, suspected, or past history of hormone-dependent tumor * genital bleeding of unknown etiology * acute thrombophlebitis or thromboembolic disorders or a past history of these conditions, associated with previous estrogen use * subjects who had adverse events during the final visit, or discontinued prematurely, or were noncompliant in vag/pd/009/usa * exposure to any investigational new drug (other than what was dispensed in vag/pd/009/usa) within the previous 30 days
evaluation of the long-term efficacy and safety of monofocal plate haptic intraocular lens

Conditions: Lens Implantation, Intraocular; Cataract

Summary: our study aims to determine the efficacy and safety of the monofocal plate haptic intraocular lens to be implanted in patients planning for cataract surgery and to determine the complications that may develop due to the lens.

this study was planned to be performed on 300 eyes with surgical indication due to cataracts in van yüzüncü yıl university faculty of medicine ophthalmology outpatient clinic. uncorrected and best-corrected visual acuity, subjective refraction, slit-light biomicroscopy, optical biometry, anterior segment optical coherence tomography, intraocular pressure, endothelial cell count in the pre-and postoperative (1st, 3rd, and 12th months) controls of the patients. fundus examination will be performed, and postoperative complications and accompanying ocular pathologies will be recorded. data before and after surgery effectiveness will be evaluated. reliability will be interpreted by considering postoperative complications.

Eligibility criteria:
inclusion criteria: * patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent; * patients of any gender * assured follow-up examinations * biometry measurement preferably compatible with the lenstar evaluation; * iol implanted into the capsular bag with iol model acriva bb udm 611 (uve material) in one or both eyes exclusion criteria: * bcva not available preoperatively or better than 0.3 logmar pre-op * patients unable to meet the limitations of the protocol or likely to non-cooperation during the trial * patients with peroperative complications (such as capsulorhexis problems that affect centralization, failure of the iol implanting into the bag, posterior capsular rupture, iris damage, vitreous loss, iol damage, etc.)

Keywords: cataract intraocular lens implantation phacoemulsification
a predictive model for inadequate bowel preparation

Conditions: Bowel Preparation

Summary: we aimed to develop a predictive model of inadequate bowel preparation and to further validate it by a randomized controlled trial.


Eligibility criteria:
inclusion criteria: * patients aged 18-75 years undergoing colonoscopy exclusion criteria: * known or suspected bowel obstruction, stricture or perforation * compromised swallowing reflex or mental status * severe chronic renal failure(creatinine clearance \< 30 ml/min) * severe congestive heart failure (new york heart association class iii or iv) * uncontrolled hypertension (systolic blood pressure \> 170 mm hg, diastolic blood pressure \> 100 mm hg) * dehydration * disturbance of electrolytes * pregnancy or lactation * hemodynamically unstable * unable to give informed consent

Keywords: adenoma bowel preparation colonoscopy predictive model randomized controlled trial
cost effectiveness in alveolar bone grafting in patients with cleft lip and palate

Conditions: Cleft Lip and Palate

Summary: the purpose of this trial is to evaluate if the use of bone morphogenic protein(bmp)/demineralized bone matrix (dbm) versus the use of autologous iliac crest bone graft (icbg) will result in an increase in total cost effectiveness for patients undergoing alveolar bone graft (abg) for cleft lip and palate (clp) and to see if patients who are treated with dbm/bmp will have reduced post-operative pain scores,reduced operative times,and similar rates of bone healing compared to conventional icbg.


Eligibility criteria:
inclusion criteria: * patient with clp(unilateral or bilateral) * radiographically evident open bone defect of the alveolus * dentition evaluated by orthodontist and cleared for abg surgery exclusion criteria: * patients without clp * previous failed repair of alveolar cleft * patients who have previously undergone successful abg * patients without an alveolar defect * patients whose parents refuse to consent to randomization * patients who have a syndromic clp

Keywords: alveolar bone graft bone morphogenic protein demineralized bone matrix cleft lip
predictors of intrauterine growth restriction

Conditions: Pre-Eclampsia

Summary: the main objectives of modern antenatal care programs are to identify high risk pregnancies then to predict any possibility of adverse pregnancy outcome as early as possible. the earliest attempts to achieve this goal were possible with the introduction of ultrasound in obstetrical practice in the 1950s. a breakthrough that enabled obstetricians to directly visualize the fetus, placenta and amniotic fluid. at first 2-dimensional (2d) imaging was employed whereby fetal biometry and placental location were detected. later on, doppler measurements \& 3-dimensional (3d) representation became feasible further revolutionizing this area


Eligibility criteria:
inclusion criteria: 1. pregnant female. 2. pregnant ± 22 to 26 weeks gestation 3. singleton pregnancy. 4. consenting to participate exclusion criteria: 1. intrauterine fetal death 2. diagnosed to have any congenital anomalies 3. symmetrical iugr 4. established fetal compromise that necessitates delivery
the oxford pain, activity and lifestyle (opal) cohort study

Conditions: Low Back Pain

Summary: the opal study is about health outcomes in older adults. the investigators are surveying 4,000 adults across england to see how health and physical activity change over time. the information that is collected will help the investigators to understand how a person's health, including conditions such as back pain, affect their mobility as they age, and provide insight into improving the management of health in older adults.

the oxford pain, activity and lifestyle (opal) study is a large cohort study of community dwelling adults (n=4000) aged 65 years and over. this cohort data will allow the investigators to describe the prevalence, severity, course and prognosis a range of musculoskeletal problems in older people. the initial focus is to evaluate the impact of back pain on important health outcomes for older people (quality of life, mobility, falls and fractures). in order to do this, the investigators will study people with and without back pain at the inception of the cohort. the opal cohort will be followed for 5 years in the first instance and the investigators will study a range of factors hypothesised to moderate and mediate the effects of back and other musculoskeletal pain for example, co-morbidities. the opal cohort will be sampled from older people registered with primary care practices. the investigators aim to develop a prognostic tool using the cohort data that will help older people, gps and other health professionals identify when lbp is a risk factor for disability, functional limitation and loss of mobility, and when lbp should be prioritised as a treatment target.

Eligibility criteria:
inclusion criteria: * registered with a primary care practice. * 65 years and over. exclusion criteria: * living in a residential care or nursing home. * has a terminal condition with a life expectancy of less than 6 months. * any substantial health or social concern that, in the opinion of the patient's gp, would place the patient at increased risk or inability to participate including known inability to provide informed consent e.g. dementia.
parental coping with challenging behavior in mucopolysaccharidosis type i-iii

Conditions: Mucopolysaccharidosis Type I; Mucopolysaccharidosis Type II; Mucopolysaccharidosis Type III; Behavior Disorders; Coping Behavior

Summary: the study quantitates behavioral challenges in mucopolysaccharidosis type i-iii and parental coping strategies

this is a prospective, cross-sectional, observational study quantitatively assessing 1. challenging behavior in children with mps, an orphan, progressive, neurodegenerative metabolic disorder, and 2. parental coping strategies for this challenging behavior. patients registered at the german society for mucopolysacchardoses giving written informed consent are eligible. the study is based on questionnaires. irb approval was obtained.

Eligibility criteria:
inclusion criteria: * diagnosis of mucopolysaccharidosis type i, ii or iii * written informed consent * patient is registered at the german society for mucopolysaccharidosis exclusion criteria: * patient / family does not give written informed consent.
effect of hula hooping as compared to walking on adipose tissue distribution, metabolic parameters and adipose tissue gene expression

Conditions: Android Obesity, Metabolic Parameters and Adipose Tissue (AT) Gene Expression

Summary: o determine effects of hula-hooping on android obesity, metabolic parameters and adipose tissue (at) gene expression.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years * central adiposity as measured by the waist circumference (\>80 cm in females and \>94 cm in males) (9) * ability to hula-hoop for a minimum of 2 minutes and to have the necessary space available for this activity either at home or at work * ability to communicate meaningfully with the investigator and legal competence to provide written informed consent exclusion criteria: * clinical or biochemical evidence of disease other than obesity as judged by history, physical examination and standard laboratory tests * excessive use of alcohol, i.e., over 20 g/day * use of medications known to affect glucose or lipid metabolism and * pregnancy or lactation
the food effect pharmacokinetic, material balance and metabolite identification of sp2086 in healthy volunteers

Conditions: Type 2 Diabetes

Summary: all eligible subjects were randomly assigned to group a and group b sequences, each sequence has 12 subjects. the sp2086 were given limosis,then after the meal,then limosis.in the study ,the investigators collected the blood samples,urine samples and fecal samples to analyze.


Eligibility criteria:
inclusion criteria: * healthy volunteers with a body mass index (bmi, a measure of a person's weight in relation to height) between 19 and 26 kg/m2 exclusion criteria: * history of diabetes * history of heart failure or renal insufficiency * urinary tract infections, or vulvovaginal mycotic infections * history of or current clinically significant medical illness as determined by the investigator * history of clinically significant allergies, especially known hypersensitivity or intolerance to lactose * known allergy to sp2086 or any of the excipients of the formulation of sp2086
a study of the safety of individualized combination therapy with copegus (ribavirin) and pegasys (peginterferon alfa-2a) in patients with chronic hepatitis c (master)

Conditions: Hepatitis C, Chronic

Summary: this open-label, non-comparative study will assess the safety and tolerability of individualized combination therapy with copegus (ribavirin) and pegasys (peginterferon alfa-2a) in patients with chronic hepatitis c. patients with hepatitis c virus (hcv) genotype 1 (group a) will receive copegus 1'000 mg or 1'200 mg daily orally for 24-72 weeks. for patients with genotype 2 or 3 hcv (group b) the copegus dose will be 800 mg daily for 16-48 weeks. patients who had previously received standard or pegylated interferons but were non-responders or with relapse (group c) will receive copegus 1'000 mg or 1'200 mg daily for up to 72 weeks. concomitant therapy with pegasys 180 mcg subcutaneously weekly will be given to all patients. anticipated time on study treatment is up to 72 weeks with a 24-week follow-up.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic hepatitis c * measurable serum hvc rna levels * compensated liver disease (child-pugh class a) * treatment-naive for standard or pegylated interferons, or non-responder or relapsing exclusion criteria: * concomitant hepatitis a or b * history of chronic liver disease not caused by hepatitis c virus * hepatocellular carcinoma * history or signs of esophageal varices haemorrhage or other conditions indicative of decompensated liver disease * treatment with any systemic anti-tumor or immunomodulatory agent (including steroids at doses exceeding physiological ones, and radiotherapy) within 6 months prior to first dose of study drug * pregnant or lactating women, or men whose partners are pregnant
the effect of preoperative education on anxiety

Conditions: Surgery; Anxiety

Summary: this randomized controlled study aimed to evaluate the effect of preoperative education on anxiety levels in patients undergoing abdominal surgery at a training hospital in istanbul. the study population included patients admitted between january and june 2024. after power analysis, patients were divided into experimental (n=40) and control (n=41) groups. the experimental group received preoperative information, while the control group received standard care. anxiety levels were assessed using the state-trait anxiety inventory (stai). data were analyzed with spss, using tests such as the mann-whitney u and wilcoxon sign tests.

as a result of this study, the anxiety levels of patients who received preoperative information training in the prevention or reduction of anxiety were found to be lower than patients who received routine care. the lower score indicated that they experienced less anxiety or were able to manage their anxiety in the experimental group.

Eligibility criteria:
inclusion criteria: * admission to the general surgery clinic for abdominal surgery in category a-b-c * must be over the age of 18 * to be literate- to be a writer * being conscious * who does not have a psychiatric disorder exclusion criteria: * exit the research during the study, * group d and e abdominal surgery has been performed * don't be under the age of 18 * unconscious patient, * who has a psychiatric disorder * patients with communication disabilities or who cannot speak turkish were determined as patients.

Keywords: surgeryanxiety
validation and clinical application of dysphagia screening questionnaire

Conditions: Dysphagia; Swallowing Disorders

Summary: the aim of this research was to develop a dysphagia screening measure and evaluate the prevalence of dysphagia and its clinical manifestation in different in age population groups.

the dysphagia screening questionnaire had the stages of validation - translation and back translation, a review of the translation and back translation committee, pre-test study (36 persons) with monolingual individuals and the test re-test study (67 subjects included). the case - control study groups were tested using dysphagia screening questionnaire and clinical screening - water drinking test. barthel index and nutrition questionnaire were used to identify the nutritional and functional state. m. d. anderson dysphagia inventory questionnaire, sf-12 questionnaire were used to assess dysphagia effects on the quality of life. the research group consisted of two subgroups - 171 nursing home residents from 3 different nursing homes and 82 outpatients of the hospital of lithuanian university of health sciences. the control group consisted of randomly selected 40 community-dwelling elderly healthy individuals.

Eligibility criteria:
inclusion criteria: * adults * consent for participating in the research * no cognitive disorders or mental illnesses exclusion criteria: * refusal to participate in the research * serious mental or cognitive conditions

Keywords: swallowing disorder dysphagia
effect of midazolam on white-coat hypertensive dental patients

Conditions: Transient Hypertension

Summary: intravenous sedation was used for dealing with transient hypertension, so-called white-coat hypertension, before dental treatment. midazolam used as a sedative also has antianxiety effect, and the mechanism is guessed that it minimizes patients' stress, resulting in the stability of blood pressure. the purpose of this randomized controlled trial (rct) is to evaluate the effect of low dose of midazolam on blood pressure and anxiety scale in white-coat hypertensive dental patients.


Eligibility criteria:
inclusion criteria: sbp\>=140mmhg or dbp\>=90mmhg measuring when the patient sits on dental chair and has settled down for 5 minutes among dental outpatients scheduling intravenous sedation with american society of anesthesiologists physical status i or ii. exclusion criteria: 1. uncontrolled or unstable hypertension 2. secondary hypertension such as hyperthyroidism and pheochromocytoma 3. taking sympathomimetic drugs 4. contraindication of midazolam such as myasthenia gravis and acute narrow-angle glaucoma 5. a pregnant woman or during lactation period 6. psychiatric disorder such as schizophrenia 7. not having intelligence enough to read, understand and write a japanese version of stai 8. judged unsuitable by a researcher

Keywords: intravenous sedation midazolam dental treatment white-coat hypertension stai dental patients transient hypertension
feasibility of action observation and repetitive task practice on upper extremity outcomes in chronic stroke survivors

Conditions: Stroke; Hemiparesis

Summary: the objective of this pilot randomized controlled single blinded, parallel-group study is to detect change of the action observation (ao) and repetitive task practice (rtp) combined practice schedule on upper limb motor impairment outcomes in chronic, moderately impaired stroke survivors.

the current proposal aims to conduct a pilot randomized controlled single blinded, parallel-group study design to detect change of the action observation (ao) and repetitive task practice (rtp) combined practice schedule on upper limb (ul) motor impairment outcomes in the chronic, moderately impaired stroke survivor. individuals will be randomized to 1) experimental conditions of ao + rtp practice schedule, or 2) control condition of placebo video (pv) + rtp, and will receive an assigned regimen from a blinded intervention therapist for one hour, 3 times per week, for 8 weeks (total of 24 sessions), and a daily 30 minute hep. a blinded assessor will complete assessments on each subject at three distinct time points of pretest, post intervention, and 1 month post intervention.

Eligibility criteria:
inclusion criteria: * experienced a stroke resulting in a upper extremity fugl meyer score \>17 \< 49 * experienced a post stroke \> 6 months * \> 24 on the folstein mini mental status examination * experienced only one stroke * discharged from all forms of physical rehabilitation intervention * visual acuity of 20/50 or greater with or without corrective lenses * \> 19 on the hooper visual organization test * unilateral stroke only * cerebral stroke * age of onset of stroke greater than 18 years old. exclusion criteria: * \< 18 years old * \> 5 on a 10-point visual analog pain scale in the affected ul * \> 2 on the modified ashworth scale in the affected ul to exclude individuals with hypertonia, spasticity, joint rigidity, and joint contracture * participating in any experimental rehabilitation or drug studies * uncontrolled cardiovascular, or pulmonary disease, or other disease that would preclude involvement in a therapeutic treatment * neurological disorder other than stroke * \> 31 on beck depression inventory ("severe depression") * unable to regularly attend treatment sessions and follow-up due to distance from the center or inadequate social support * cerebellar stroke with ataxia

Keywords: stroke hemiparesis